The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia

228 Pages·2015·20.9 MB·English

by  Annemieke Leunis

A N N E M I E K E L E U N I S
T he cost-eff ectiveness
of personalized
medicine strategies
in acute myeloid
leukemia
A N N E M I E K E L E U N I S The cost-eff ectiveness of personalized medicine strategies in acute myeloid leukemia
The cost-efectiveness of
personalized medicine strategies in
acute myeloid leukemia
Annemieke Leunis
Layout and printing: Optima Grafsche Communicatie, Rotterdam, The Netherlands
© Annemieke Leunis, 2015
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system
or transmitted in any form or by any means, without prior written permission of the
author or, when appropriate, of the publishers of the publications.
ISBN: 978-94-6169-679-3
Funding
The studies in this thesis were supported by the Center for Translational Molecular Medi-
cine (CTMM), project BioCHIP (grant 030-102), the Netherlands Organization for Health
Research and Development (ZonMw) and the Dutch Society of Hematology.
The cost-efectiveness of
personalized medicine strategies in
acute myeloid leukemia
De kostenefectiviteit van geïndividualiseerde
behandelstrategieën in acute myeloïde leukemie
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnifcus
prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
donderdag 18 juni 2015 om 13.30 uur
door
Annemieke Leunis
geboren te Strijen
PromoTiecommissie:
Promotoren:
Prof.dr. C.A. Uyl-de Groot
Prof.dr. B. Löwenberg
overige leden:
Prof.dr. W.B.F. Brouwer
Prof.dr. J.J. van Busschbach
Prof.dr. N.M.A. Blijlevens
copromotor:
Dr. W.K. Redekop
conTenTs
Chapter 1. General Introduction 7
Chapter 2. The costs of initial treatment for patients with acute myeloid 19
leukemia in the Netherlands
Chapter 3. Mapping QLQ-C30, HAQ and MSIS-29 on EQ-5D 33
Chapter 4. Condition-specifc preference-based measures: beneft or burden? 61
Chapter 5. Impaired health-related quality of life in acute myeloid leukemia 89
survivors: a single-center study
Chapter 6. How to measure quality of life utilities in acute leukemia patients? 105
A comparison of the feasibility, validity and reliability of the
generic questionnaire EQ-5D-5L and the disease-specifc QLQ-PBM.
Chapter 7. The development and validation of a decision-analytic model 121
representing the full disease course of acute myeloid leukemia
Chapter 8. Methodological recommendations for cost-efectiveness analyses 147
of personalized medicine strategies
Chapter 9. General discussion 167
Chapter 10. Summary 185
Samenvatting 191
List of abbreviations 197
Dankwoord 199
PhD portfolio 203
About the author 207
References 209
Ch apter 1 1
General Introduction
2
3
4
5
6
7
8
9
10